PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.

Abstract Epidermal growth factor receptor (EGFR) mutation testing is standard-of-care for advanced non-small cell lung cancer (NSCLC). Outcomes of second-/third-line compared to first-line tyrosine kinase inhibitors (TKIs) have shown conflicting results. We investigated utilization of molecular diagnostics and the outcomes of treatment with first-/second-line TKIs in patients with advanced NSCLC.
PMID
Related Publications

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.

Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.

The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.

Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

Authors

Mayor MeshTerms
Keywords

EGFR

NSCLC

molecular testing

non-small cell lung cancer

Journal Title anticancer research
Publication Year Start




PMID- 29277800
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Utilization of Molecular Testing and Survival Outcomes of Treatment with First-
      or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer 
      in a Dutch Population.
PG  - 393-400
AB  - BACKGROUND/AIM: Epidermal growth factor receptor (EGFR) mutation testing is
      standard-of-care for advanced non-small cell lung cancer (NSCLC). Outcomes of
      second-/third-line compared to first-line tyrosine kinase inhibitors (TKIs) have 
      shown conflicting results. We investigated utilization of molecular diagnostics
      and the outcomes of treatment with first-/second-line TKIs in patients with
      advanced NSCLC. MATERIALS AND METHODS: Retrospective analysis was carried out of 
      2,206 patients with stage IIIb/IV NSCLC treated between 2008 and 2014 in four
      hospitals in the Netherlands. RESULTS: The rate of performing molecular
      diagnostics increased from 20.8% to 74.4% in the study period. The median overall
      survival of EGFR mutation-positive patients treated with TKIs was superior
      compared to EGFR mutation-negative patients treated with chemotherapy (720 vs.
      274 days, p<0.0001). No difference in overall survival was found between EGFR
      mutation-positive patients treated only with TKIs compared to those treated with 
      chemotherapy prior to TKIs, or upon progression under TKIs. CONCLUSION: The rate 
      of EGFR testing has improved, increasing the number of patients eligible for
      targeted therapy. Chemotherapy, prior or subsequent to TKIs, for the treatment of
      EGFR mutation-positive patients, did not result in significantly better overall
      survival compared to that achieved with TKIs alone.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Sluga, Romina
AU  - Sluga R
AD  - Department of Pulmonary Diseases, St. Antonius Hospital, Nieuwegein/Utrecht, the 
      Netherlands/Santeon Care for Outcomes NSCLC Study Group, Santeon Hospital Group, 
      Utrecht, the Netherlands [email protected]
FAU - VAN DEN Borne, Ben E E M
AU  - VAN DEN Borne BEEM
AD  - Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, the
      Netherlands/Santeon Care for Outcomes NSCLC Study Group, Santeon Hospital Group, 
      Utrecht, the Netherlands.
FAU - Roepman, Paul
AU  - Roepman P
AD  - Department of Pathology, St. Antonius Hospital, Nieuwegein/Utrecht, the
      Netherlands/Santeon Care for Outcomes NSCLC Study Group, Santeon Hospital Group, 
      Utrecht, the Netherlands.
FAU - Peters, Bas J M
AU  - Peters BJM
AD  - Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein/Utrecht, the
      Netherlands/Santeon Care for Outcomes NSCLC Study Group, Santeon Hospital Group, 
      Utrecht, the Netherlands.
FAU - Kastelijn, Elisabeth A
AU  - Kastelijn EA
AD  - Department of Pulmonary Diseases, Gelderse Vallei Hospital, Ede, the Netherlands.
FAU - Schramel, Franz M N H
AU  - Schramel FMNH
AD  - Department of Pulmonary Diseases, St. Antonius Hospital, Nieuwegein/Utrecht, the 
      Netherlands/Santeon Care for Outcomes NSCLC Study Group, Santeon Hospital Group, 
      Utrecht, the Netherlands.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - EGFR
OT  - NSCLC
OT  - molecular testing
OT  - non-small cell lung cancer
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/01 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/393 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):393-400.